ليتروزول تيڤع

Country: Ísrael

Tungumál: arabíska

Heimild: Ministry of Health

Virkt innihaldsefni:

LETROZOLE 2.5 MG

Fáanlegur frá:

TEVA PHARMACEUTICAL INDUST.LTD

ATC númer:

L02BG04

Lyfjaform:

TABLETS

Stjórnsýsluleið:

PER OS

Framleitt af:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Meðferðarhópur:

LETROZOLE

Ábendingar:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Leyfisdagur:

2010-01-01